Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The oral formulations are expected to dramatically expand the addressable market: Lilly CEO Dave Ricks has noted that fewer than 1 in 10 eligible patients currently take a GLP-1, partly due to needle aversion
Significant progress has been made on approaches targeting GPCRs such as single peptides that simultaneously activate GIP and/or GCGR in addition to GLP1, oral tablet formulation of GLP-1, small molecules nonpeptidic oral GLP1R and fixed-dose combination as well as add-on therapy for patients already treated with a GLP-1 agonist
was supported by Pels Family Center Fellowship
Designed for advanced endocrinological, neuroendocrine, and biochemical research, this bundle is engineered for laboratory environments where data integrity and compound stability are critical
